AU2011346733C1 - Novel fused pyridine compounds as casein kinase inhibitors - Google Patents
Novel fused pyridine compounds as casein kinase inhibitors Download PDFInfo
- Publication number
- AU2011346733C1 AU2011346733C1 AU2011346733A AU2011346733A AU2011346733C1 AU 2011346733 C1 AU2011346733 C1 AU 2011346733C1 AU 2011346733 A AU2011346733 A AU 2011346733A AU 2011346733 A AU2011346733 A AU 2011346733A AU 2011346733 C1 AU2011346733 C1 AU 2011346733C1
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- pyrazol
- fluorophenyl
- pyrrolo
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061425213P | 2010-12-20 | 2010-12-20 | |
| US61/425,213 | 2010-12-20 | ||
| PCT/IB2011/055489 WO2012085721A1 (en) | 2010-12-20 | 2011-12-06 | Novel fused pyridine compounds as casein kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2011346733A1 AU2011346733A1 (en) | 2013-07-18 |
| AU2011346733B2 AU2011346733B2 (en) | 2015-08-13 |
| AU2011346733C1 true AU2011346733C1 (en) | 2015-12-24 |
Family
ID=45446116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011346733A Ceased AU2011346733C1 (en) | 2010-12-20 | 2011-12-06 | Novel fused pyridine compounds as casein kinase inhibitors |
Country Status (23)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012004997A (es) * | 2009-10-28 | 2012-06-12 | Pfizer | Derivados de imidazol como inhibidores de la caseina quinasa. |
| US9938269B2 (en) * | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| EP2935272B1 (en) * | 2012-12-21 | 2017-02-22 | Bristol-Myers Squibb Company | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors |
| WO2015163446A1 (ja) * | 2014-04-25 | 2015-10-29 | 協和発酵キリン株式会社 | イミダゾール化合物の製造方法 |
| JP2017222576A (ja) * | 2014-10-31 | 2017-12-21 | 石原産業株式会社 | 有害生物防除剤 |
| CN107365315B (zh) * | 2016-05-11 | 2024-08-09 | 国药集团国瑞药业有限公司 | 一种吡唑类化合物、其晶型及其制备方法 |
| US10973820B2 (en) | 2017-12-13 | 2021-04-13 | Facio Intellectual Property B.V. | Compounds for treatment of diseases related to DUX4 expression |
| TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| EP4126878A4 (en) * | 2020-03-27 | 2024-07-10 | Gritscience Biopharmaceuticals Co., Ltd. | COMPOUNDS AS CASEIN KINASE INHIBITORS |
| CN115335057A (zh) * | 2020-03-27 | 2022-11-11 | 北京原基华毅生物科技有限公司 | 抑制酪蛋白激酶的方法 |
| AR122711A1 (es) | 2020-06-25 | 2022-09-28 | Alchemedicine Inc | COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA |
| CN111808102B (zh) * | 2020-08-03 | 2021-12-31 | 南通大学 | 一种3-甲氧基-6,7-二氢-5H-吡咯并[3,4-b]吡啶盐酸盐及其合成方法 |
| KR20230069169A (ko) * | 2020-09-17 | 2023-05-18 | 얀센 파마슈티카 엔.브이. | 카제인 키나제 1 델타 조절제 |
| JP2023541465A (ja) * | 2020-09-17 | 2023-10-02 | ヤンセン ファーマシューティカ エヌ．ベー． | カゼインキナーゼ１デルタモジュレーター |
| WO2022115301A1 (en) * | 2020-11-24 | 2022-06-02 | Merck Sharp & Dohme Corp. | Modified isoindolinones as glucosylceramide synthase inhibitors |
| CN116888126B (zh) * | 2020-12-15 | 2026-03-17 | 北京原基华毅生物科技有限公司 | 一种酪蛋白激酶抑制剂的化合物 |
| US20230053307A1 (en) * | 2021-07-19 | 2023-02-16 | Buddhist Tzu Chi Medical Foundation | Method for preventing or treating skin disorders and conditions |
| CN119487030A (zh) * | 2022-06-14 | 2025-02-18 | 北京原基华毅生物科技有限公司 | 作为酪蛋白激酶抑制剂的化合物的盐和/或晶形 |
| CN117362303B (zh) * | 2022-07-02 | 2026-02-03 | 黑龙江联顺生物科技有限公司 | 一种生物素中间体环酐的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011042389A2 (de) * | 2009-10-09 | 2011-04-14 | Bayer Cropscience Ag | Phenylpyri(mi)dinylazole |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0151962A3 (en) | 1984-01-25 | 1985-10-02 | Beecham Group Plc | Pyrazolopyridine derivatives |
| NZ501112A (en) * | 1997-05-22 | 2002-10-25 | G | Substituted pyrazoles as p38 kinase inhibitors |
| US6610688B2 (en) * | 1999-12-21 | 2003-08-26 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| US20070010523A1 (en) | 2005-06-22 | 2007-01-11 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| US7897595B2 (en) | 2006-05-26 | 2011-03-01 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
| MX2012004997A (es) * | 2009-10-28 | 2012-06-12 | Pfizer | Derivados de imidazol como inhibidores de la caseina quinasa. |
-
2011
- 2011-12-06 EP EP17151228.8A patent/EP3181133B1/en active Active
- 2011-12-06 RS RS20170387A patent/RS55897B1/sr unknown
- 2011-12-06 PL PL17151228T patent/PL3181133T3/pl unknown
- 2011-12-06 DK DK11805210.9T patent/DK2654750T3/en active
- 2011-12-06 JP JP2013545540A patent/JP5684923B2/ja active Active
- 2011-12-06 CA CA2819961A patent/CA2819961C/en active Active
- 2011-12-06 PT PT17151228T patent/PT3181133T/pt unknown
- 2011-12-06 MX MX2013005833A patent/MX338551B/es active IP Right Grant
- 2011-12-06 ES ES11805210.9T patent/ES2623387T3/es active Active
- 2011-12-06 LT LTEP11805210.9T patent/LT2654750T/lt unknown
- 2011-12-06 SI SI201131141A patent/SI2654750T1/sl unknown
- 2011-12-06 EP EP11805210.9A patent/EP2654750B1/en active Active
- 2011-12-06 DK DK17151228.8T patent/DK3181133T3/da active
- 2011-12-06 PL PL11805210T patent/PL2654750T3/pl unknown
- 2011-12-06 SG SG2013036934A patent/SG190802A1/en unknown
- 2011-12-06 RS RS20191036A patent/RS59098B1/sr unknown
- 2011-12-06 HR HRP20170484TT patent/HRP20170484T1/hr unknown
- 2011-12-06 AU AU2011346733A patent/AU2011346733C1/en not_active Ceased
- 2011-12-06 HU HUE17151228A patent/HUE047089T2/hu unknown
- 2011-12-06 SI SI201131784T patent/SI3181133T1/sl unknown
- 2011-12-06 PT PT118052109T patent/PT2654750T/pt unknown
- 2011-12-06 CN CN201180061257.2A patent/CN103260622B/zh active Active
- 2011-12-06 HU HUE11805210A patent/HUE032405T2/en unknown
- 2011-12-06 ES ES17151228T patent/ES2744099T3/es active Active
- 2011-12-06 LT LTEP17151228.8T patent/LT3181133T/lt unknown
- 2011-12-06 KR KR1020137015822A patent/KR101590236B1/ko not_active Expired - Fee Related
- 2011-12-06 WO PCT/IB2011/055489 patent/WO2012085721A1/en not_active Ceased
- 2011-12-13 US US13/323,883 patent/US8536164B2/en active Active
- 2011-12-19 AR ARP110104787A patent/AR084412A1/es not_active Application Discontinuation
-
2013
- 2013-05-13 ZA ZA2013/03453A patent/ZA201303453B/en unknown
- 2013-06-13 IL IL226948A patent/IL226948A/en active IP Right Grant
-
2015
- 2015-01-14 JP JP2015005142A patent/JP5876596B2/ja active Active
-
2017
- 2017-03-27 CY CY20171100378T patent/CY1118772T1/el unknown
-
2019
- 2019-08-14 HR HRP20191469 patent/HRP20191469T1/hr unknown
- 2019-08-21 CY CY20191100892T patent/CY1122062T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011042389A2 (de) * | 2009-10-09 | 2011-04-14 | Bayer Cropscience Ag | Phenylpyri(mi)dinylazole |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011346733B2 (en) | Novel fused pyridine compounds as casein kinase inhibitors | |
| CA2777632C (en) | Imidazole derivatives as casein kinase inhibitors | |
| AU2017288755B2 (en) | Novel compound or pharmaceutically acceptable salt thereof | |
| AU2018388406B2 (en) | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors | |
| KR20220061958A (ko) | Cd38의 억제제로서의 헤테로바이사이클릭 아미드 | |
| HK1188145B (en) | Novel fused pyridine compounds as casein kinase inhibitors | |
| CA3222054A1 (en) | 2, 8-diazaspiro[4.5]decane compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 08 SEP 2015 . |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 08 SEP 2015 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: BIOGEN MA INC. Free format text: FORMER OWNER(S): PFIZER INC. |